Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management.
- Author:
Boon Hui CHAN
1
;
Ruixiang YEE
1
;
Rukshini PUVANENDRAN
2
;
Seng Bin ANG
2
Author Information
- Publication Type:Journal Article
- Keywords: MRONJ; bisphosphonates; osteonecrosis; osteoporosis
- MeSH: Aged; Bone Density Conservation Agents; adverse effects; therapeutic use; Denosumab; adverse effects; therapeutic use; Diphosphonates; adverse effects; therapeutic use; Humans; Jaw Diseases; chemically induced; prevention & control; Osteonecrosis; chemically induced; prevention & control; Osteoporosis; complications; drug therapy; Osteoporotic Fractures; complications; drug therapy; Risk Factors; Singapore; Treatment Outcome
- From:Singapore medical journal 2018;59(2):70-75
- CountrySingapore
- Language:English
- Abstract: Osteoporosis is a major, growing healthcare issue. This is especially of concern in an ageing population like that of Singapore. Osteoporotic patients are at risk of fractures, which can result in increased morbidity and mortality. The use of antiresorptive therapy with bisphosphonates or denosumab has been proven to reduce fracture risk. However, the use of these medications has rarely been associated with the development of osteonecrosis of the jaw, a potentially debilitating condition affecting one or both jaws. Appropriate understanding of the patient's antiresorptive therapy regime, as well as early institution of preventive dental measures, can play an important role in preventing medication-related osteonecrosis of the jaw (MRONJ). Regular monitoring and prompt referral to specialist care is warranted for patients with established MRONJ.
